Phase 2 Colorectal Cancer Trial, Recruiting NCT05959356 Sponsor: Sun Yat-sen University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT05959356
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older and are expected to live for at least 12 more weeks
  • You have been diagnosed with a specific type of colorectal cancer (called RAS and BRAF wild-type, MSS metastatic colorectal adenocarcinoma) confirmed by a tissue or cell sample — this excludes cancers starting in the appendix or anus
  • Your cancer is at an advanced stage (Stage IV) and started on the left side of the colon or rectum, and there is at least one tumour that can be measured on a scan
  • You have not previously received any systemic treatments (such as chemotherapy, targeted therapies, or immunotherapy) for advanced or metastatic colorectal cancer — note: if your cancer came back during or within 6 months of completing earlier preventative chemotherapy, that treatment counts as your first treatment
  • Your general health and ability to carry out daily activities is rated as good to fairly good (confirm with trial site)
  • Your blood test results within 7 days before starting treatment show that your blood counts, liver function, and kidney function are within acceptable ranges (confirm with trial site)
  • If you are a woman who could become pregnant, you must have a negative blood pregnancy test before starting the trial
  • You are willing and able to sign a consent form, follow the study plan, and not join any other clinical trials at the same time

Who may not be able to join:

  • You currently have another active cancer, unless it has been in remission for 5 or more years or was a non-invasive cancer successfully treated
  • You have an active gastrointestinal condition such as a duodenal ulcer, ulcerative colitis, or bowel blockage that could increase the risk of bleeding or a bowel perforation
  • You have had a stroke, mini-stroke, blood clot in the lungs, or a deep vein blood clot within the past 12 months
  • You have had a heart attack, severe chest pain, significant heart failure, or serious heart rhythm problems within the past 12 months
  • You have taken antibiotics for 7 or more days within the past 4 weeks, or you have had an unexplained fever above 38.5°C recently (unless the fever is linked to the tumour itself)
  • You have uncontrolled fluid build-up around your lungs, abdomen, or heart in the 14 days before joining, despite receiving treatment for it
  • You still have significant unresolved side effects (Grade 2 or higher) from previous cancer treatments, apart from anaemia, hair loss, or skin discolouration
  • You have a lung condition such as interstitial lung disease, non-infectious pneumonia, or pulmonary fibrosis, or you have uncontrolled diabetes or high blood pressure
  • You are known to have HIV, or you have active hepatitis B or C, or both
  • You have a known or suspected allergy to any of the drugs used in this trial
  • You are currently pregnant or breastfeeding
  • You are a woman who has had a period within the last 2 years and does not use or is unwilling to use effective non-hormonal contraception, or you are a man who is able to father children (confirm with trial site)
  • You have other significant physical or mental health conditions or abnormal test results that the trial team considers would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yanhong Deng, Ph.D, Sixth Affiliated Hospital, Sun Yat-sen University

Phone: 86-13925106525

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 November 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov